pharmacology

AfaSci Inc. is a San Francisco Bay Area biopharmaceutical company developing life-changing pain and epilepsy medications. It provides contract services to the R&D community, leveraging drug discovery expertise in pain, epilepsy, stroke and Alzheimer's disease, along with proprietary instruments for automated rodent behavioral monitoring.

behavioral assaysdrug discoveryEEG/EMG in vivoelectrophysiologyhistopathologyimmunohistochemistryIn vivo PK/PDMEA-64 recordingsneurobehavior toxicity testingpatch clamp

Alpha Genesis is an AAALAC-accredited, USDA-licensed preclinical research and animal-resource partner supporting pharmaceutical, biotechnology, academic, and government sponsors. It designs and executes preclinical development programs across rodent and nonhuman primate models, from pharmacology and PK/PD through toxicology, bioanalysis, and IND-enabling work, and operates the largest NHP colony in the United States with 13,000+ NHPs across three facilities.

bioanalysiscatheterizationdevice implantationFlow CytometryhistologyIHCimmunoassaysin vivo researchISH/RNAscopeLC-MS/MSmicrosurgeryMRIpathologyPET/CT imagingPK/PDqPCRSPECT/CT imagingtelemetrytoxicology

CCS Associates (CCSA) is a small business providing leading-edge scientific services in product discovery and development to government agencies and the pharmaceutical and biotech industries. It is a full-service CRO offering services from discovery to approval, with more than 40 years of client success. CCSA was founded by Caroline C. Sigman, PhD, and its projects have led to 5300+ IND, NDA, CTA, DMF, IDE, and INAD submissions.

Bioinformaticsclinical trial monitoringeCTD publishingPharmacovigilanceRegulatory Affairsscientific and medical writingstrategic-planningtoxicology

Cognitive Synergy Corporation is a biotechnology company developing novel small-molecule therapies for Alzheimer's disease and related neurodegenerative disorders. Its lead candidate is designed to restore synaptic health while reducing amyloid and tau pathology, aiming to be a disease-modifying treatment. The company integrates translational biomarkers, pharmacology, and behavioral outcomes and is progressing its small molecule through IND-enabling studies toward early clinical trials.

IND-enabling studiespreclinical researchsmall molecule drug discoverytranslational biomarkers

Crestone, Inc. is a clinical stage biopharmaceutical and biotech company in Boulder, Colorado focused on inventing and developing novel mechanism of action small molecule drugs for serious bacterial infections. Its pipeline includes antibacterial agents targeting C. difficile infection, resistant Gram-positive infections such as MRSA and VRE, and nontuberculous mycobacterial (NTM) disease and tuberculosis.

analytical chemistryanalytical (LC-MS, NMR)antimicrobial susceptibility testing according to CLSI guidelinesbiochemistrycell biologymedicinal chemistry (synthesis, analog design)microbiological profilingMicrobiologyprocess chemistryScale upsynthetic organic chemistry

Estrigenix Therapeutics, Inc. was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and prevent hot flashes and dementia in post-menopausal women. It is a privately held pharmaceutical company working on a family of compounds to address menopause symptoms, moderating hot flashes and improving memory without the risks of breast cancer and stroke associated with traditional hormone replacement therapy, based on expertise in estrogen biology.

clinical trialsdrug discovery and developmentestrogen biology researchmedicinal chemistry

FAKnostics is a biopharmaceutical company developing therapeutics and diagnostics based on its Focal Adhesion Kinase (FAK) platform technology to combat metastatic cancers and fibrosis. Its proprietary hydrocarbon-stapled peptide FN-2012 blocks the FAK FAT domain, and its FAKnosTEST companion diagnostic detects cancer in early stages. The company reports more than 30 years of FAK research leadership and has 3 pre-clinical programs in fibrotic diseases.

computational drug discoverydrug discoveryimmunohistochemical (IHC) diagnosticsin-vitro approachesin vivo studiesstructure-based drug design